Sedana Medical AB (publ) (SEDANA: FN Stockholm) announced on January 27, 2022 that the National Institute of Health and Care Excellence (NICE), has issued medical technology guidance recommending Sedaconda ACD for enabling the delivery of inhaled sedation in adults in an intensive care setting as an alternative to intravenous sedation.^[1] This is the first time that NICE has recommended the use of a device for inhaled sedation for intensive care units (ICU) in England.

The recommendation of Sedaconda ACD (Anaesthetic Conserving Device), previously known as AnaConDa, as an option for delivering inhaled sedation has been made as the volatile anaesthetics isoflurane or sevoflurane are being considered.^[1] Sedaconda (isoflurane) is approved for sedation of mechanically ventilated adult patients during intensive care in 14 European countries and is currently being reviewed by the UK Medicines and Healthcare products Regulatory Agency.^[1]

This recommendation is based on clinical evidence comprising 21 studies and is supported by the economic model structure submitted to NICE, which demonstrated cost-savings.^[1] Calculations showed that over a 30-day period, Sedaconda ACD when used with isoflurane has the potential to provide cost savings of almost £4,000 per adult, when compared with existing ICU sedation standard of care.^[1] 

“The guidance from NICE is a positive milestone for ICU technology in providing safe and effective inhaled sedation, with benefits for both clinicians and patients. Not only does Sedaconda ACD demonstrate clinical-effectiveness but also cost-efficiencies for ICUs, allowing clinicians to consider a cost-effective alternative to IV sedation,” said Dr Anil Hormis, Consultant in Anaesthesia and Critical Care Medicine, Rotherham NHS Trust.

“Today’s guidance from NICE not only points at the multiple patient categories that can benefit from inhaled sedation, but also at the health economic benefits of our therapy,” said Dr Peter Sackey, Chief Medical Officer, Sedana Medical. “We are pleased that the clinical benefits of inhaled sedation have been recognised and look forward to continuing this collaboration with NICE, as we work towards improving patients’ life during and beyond sedation.”

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, This email address is being protected from spambots. You need JavaScript enabled to view it..

About Sedaconda ACD^[2]

Sedaconda ACD is a medical device enabling delivery of inhaled anaesthetics to invasively ventilated patients. The Sedaconda ACD is inserted in the breathing circuit between the endotracheal tube (ET tube) and the Y-piece and contains an evaporator which enables vaporisation of inhaled anaesthetics. The use of a carbon filter in Sedaconda ACD means that approximately 90% of exhaled anaesthetic is adsorbed during expiration and reflected to the patient, which reduces the amount of drug consumed.

Sedaconda ACD is approved in more than 30 countries, globally. For further information on Sedaconda ACD, please refer to the Instructions for Use.

For more information about Sedana Medical please visit: https://sedanamedical.com/about/

^[1] National Institute of Health and Care Excellence. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care. Medical Technologies Guidance [MTG65]. Available at: https://www.nice.org.uk/guidance/mtg65 Last accessed: January 2022

^[2] Sedaconda ACD Instructions for Use. Available at: https://sedanamedical.com/media/2khe3k1l/ifu_sedaconda-acd-l_1021rev3-v1.pdf. Last accessed: January 2022